EMG
SAGE

Ellington Management Group’s Sage Therapeutics SAGE Stock Holding History

Ellington Management Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,800
Closed -$268K – 672
2018
Q4 		$268K Buy
+2,800
New +$320K 0.08% 248
2018
Q2 		– Sell
-4,400
Closed -$709K – 799
2018
Q1 		$709K Buy
+4,400
New +$747K 0.05% 317

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Ellington Management Group's SAGE Position: Q1 2019 in Review

Ellington Management Group sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 2,800 shares — an estimated $268K sold.

Ellington Management Group first reported a position in SAGE in Q1 2018 and held it in 2 quarters. The position peaked at $709K in Q1 2018. 268 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • Ellington Management Group reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Ellington Management Group sold 2,800 Sage Therapeutics shares in Q1 2019, an estimated $268K.
  • Ellington Management Group first reported a position in Sage Therapeutics in Q1 2018 and held it in 2 quarters.
  • Ellington Management Group's Sage Therapeutics position peaked at $709K in Q1 2018.
  • 268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on Ellington Management Group's 13F filing for Q1 2019, filed 15 May 2019.